SEHK:1672Biotechs
Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed?
Ascletis Pharma recently filed a follow-on equity offering of HK$843.54 million via a subsequent direct listing, issuing 69,256,000 ordinary shares at HK$12.18 each.
The fundraising follows positive Phase III data for denifanstat in moderate-to-severe acne and progress with ASC30 in metabolic disease, underscoring Ascletis’s late-stage pipeline momentum.
We’ll now explore how this combination of positive Phase III acne data and a sizable equity raise shapes Ascletis Pharma’s investment...